Andrew Guggenhime, PRESIDENT AND CFO at Vaxcyte, Inc. (PCVX), sold 15,514 shares at $60.28 ($942K) on 2024-01-18, disclosed to the SEC on 2024-01-19.
Scheduled sale ($942k) by PRESIDENT AND CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.28 | 4,387 | $264K | 28.1% |
| 2 | $60.28 | 4,387 | $264K | 28.1% |
| 3 | $61.19 | 3,127 | $191K | 20.3% |
| 4 | $61.19 | 3,127 | $191K | 20.3% |
| 5 | $61.88 | 463 | $29K | 3.0% |
| 6 | $63.35 | 23 |
| $1K |
| 0.2% |
| Total | $60.70 avg | 15,514 | $942K | 100% |
| Filing → |
| PCVX | SELL | 2026-06-18 | $530K | — | Filing → |
| PCVX | SELL | 2025-02-19 | $1.3M | — | Filing → |
| PCVX | SELL | 2025-01-22 | $1.4M | — | Filing → |